Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3602911rdf:typepubmed:Citationlld:pubmed
pubmed-article:3602911lifeskim:mentionsumls-concept:C0027051lld:lifeskim
pubmed-article:3602911lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:3602911lifeskim:mentionsumls-concept:C0597298lld:lifeskim
pubmed-article:3602911lifeskim:mentionsumls-concept:C1880186lld:lifeskim
pubmed-article:3602911lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:3602911lifeskim:mentionsumls-concept:C0392762lld:lifeskim
pubmed-article:3602911lifeskim:mentionsumls-concept:C1533716lld:lifeskim
pubmed-article:3602911pubmed:issue4lld:pubmed
pubmed-article:3602911pubmed:dateCreated1987-8-12lld:pubmed
pubmed-article:3602911pubmed:abstractTextUsing an electrophoretic method, the changes in the catalytic activities of three CK-MM isoforms (MM1, MM2, MM3) and two CK-MB isoforms (MB1, MB2) in the serum of 13 patients with acute myocardial infarction (AMI) have been monitored for 3 days after the onset of chest pain. In post-AMI period, MM3 reaches a peak first, 17 h after infarction (394 U/l), followed by MB2 (17.3 h, 190 U/l), MB1 (20.6 h, 82 U/l), MM2 (28.7 h, 637 U/l), and MM1 (32 h, 780 U/l). According to their faster decay from circulation, MB2 and MM3 have higher fractional disappearance rates (-0.035 and -0.026 per hour, respectively). The MM3/MM1 activity ratio rises beyond the upper limit found in healthy subjects within about 3 h after onset of symptoms and peaks 9.3 h after AMI, even earlier than peaks of isoforms. These characteristics make the ratio an earlier and more sensitive indicator of acute enzyme release from necrotic myocardium.lld:pubmed
pubmed-article:3602911pubmed:languageenglld:pubmed
pubmed-article:3602911pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3602911pubmed:citationSubsetIMlld:pubmed
pubmed-article:3602911pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3602911pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3602911pubmed:statusMEDLINElld:pubmed
pubmed-article:3602911pubmed:monthJunlld:pubmed
pubmed-article:3602911pubmed:issn0036-5513lld:pubmed
pubmed-article:3602911pubmed:authorpubmed-author:PanteghiniMMlld:pubmed
pubmed-article:3602911pubmed:authorpubmed-author:CalarcoMMlld:pubmed
pubmed-article:3602911pubmed:issnTypePrintlld:pubmed
pubmed-article:3602911pubmed:volume47lld:pubmed
pubmed-article:3602911pubmed:ownerNLMlld:pubmed
pubmed-article:3602911pubmed:authorsCompleteYlld:pubmed
pubmed-article:3602911pubmed:pagination325-9lld:pubmed
pubmed-article:3602911pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:meshHeadingpubmed-meshheading:3602911-...lld:pubmed
pubmed-article:3602911pubmed:year1987lld:pubmed
pubmed-article:3602911pubmed:articleTitleSerum isoforms of creatine kinase MM and MB in myocardial infarction. An appraisal of quantitative, clinical and pathophysiological information.lld:pubmed
pubmed-article:3602911pubmed:publicationTypeJournal Articlelld:pubmed